BioNTech’s Bold Transformation: Pursuing mRNA Cancer Therapies Amid Financial Turbulence
BioNTech transitions focus from COVID-19 vaccines to pioneering mRNA-driven cancer therapies, amid reduced vaccine demand. Latest earnings reveal a profit of €1.08 per share, exceeding expectations but down from previous…